Official Title
Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
Brief Summary

This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.

Systemic Lupus Erythematosus
Rheumatoid Arthritis
Sjogren's Syndrome
Psoriatic Arthritis

Other: Questionnaire by phone call

2 questionnaires : at inclusion and 4 months later. The exposure to hydroxychloroquine and the history of autoimmune disease is determined during the phone call along with other exposure factors. The symptoms presented by the patient are classified in "Suggestive of a COVID-19 infection" or "Not suggestive of COVID-19 infection" by a team of internists and infectious diseases specialists, by studying the questionnaires after the completion in a blind-manner regarding the hydroxychloroquine intake.

Eligibility Criteria

Inclusion Criteria:

- History of Systemic Lupus Erythematosus, Rheumatoid arthritis, Sjogren's Syndrome or
Psoriatic Arthritis.

Exclusion Criteria:

- beginning, or end, of an hydroxychloroquine treatment between Jan 1, 2020 and day of
the phone call.

- Bad treatment compliance

Eligibility Gender
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A

Fondation Adolphe de Rothschild
Paris, France

Guillaume DEBELLEMANIERE, MD, Principal Investigator
Fondation Adolphe de Rothschild

Fondation Ophtalmologique Adolphe de Rothschild
NCT Number
MeSH Terms
Arthritis, Psoriatic
Sjogren's Syndrome
Lupus Erythematosus, Systemic
Autoimmune Diseases